Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,90 € ↑0,30 (2,21%)
2026-06-05
DEL PRIS
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionBnp Paribas Arbitrage, Sa
Latest Disclosed Ownership215,639 shares
Latest Disclosed Value $ 3,499,821
Bnp Paribas Arbitrage, Sa reports 33.51% decrease in ownership of 0TB / Theravance Biopharma, Inc.

On May 12, 2026 - Bnp Paribas Arbitrage, Sa filed a 13F-HR form disclosing ownership of 215,639 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $2,846,435 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 324,318 shares of Theravance Biopharma, Inc.. This represents a change in shares of -33.51% during the quarter. The current value of the position is $2,997,382 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Theravance Biopharma Equity G8807B106 215,639 -108,679 -33.51 3,500 -42.33 0.0002
2026-02-10 2025-12-31 13F Theravance Biopharma Equity G8807B106 324,318 -49,282 -13.19 6,068 11.24 0.0027
2025-11-13 2025-09-30 13F Theravance Biopharma Equity G8807B106 373,600 -13,872 -3.58 5,455 27.64 0.0029
2025-08-14 2025-06-30 13F Theravance Biopharma Equity G8807B106 387,472 91,300 30.83 4,274 61.61 0.0024
2025-05-14 2025-03-31 13F Theravance Biopharma Equity G8807B106 296,172 -9,443 -3.09 2,645 -8.03 0.0016
2025-02-14 2024-12-31 13F Theravance Biopharma Equity G8807B106 305,615 135 0.04 2,876 16.77 0.0016
2024-11-13 2024-09-30 13F Theravance Biopharma Equity G8807B106 305,480 143,781 88.92 2,462 79.58 0.0017
2024-08-13 2024-06-30 13F Theravance Biopharma Equity G8807B106 161,699 128,241 383.29 1,371 357.00 0.0011
2024-05-01 2024-03-31 13F Theravance Biopharma Equity G8807B106 33,458 7,851 30.66 300 4.53 0.0003
2024-02-14 2023-12-31 13F/A-2 Theravance Biopharma Equity G8807B106 25,607 11,813 85.64 288 141.18 0.0003
2024-02-07 2023-12-31 13F/A-1 Theravance Biopharma Equity G8807B106 25,607 11,813 288 0.0000
2024-02-07 2023-12-31 13F Theravance Biopharma Equity G8807B106 25,607 288
2023-11-14 2023-09-30 13F Theravance Biopharma Equity G8807B106 13,794 -2,488 -15.28 119 -29.17 0.0002
2023-08-09 2023-06-30 13F Theravance Biopharma Equity G8807B106 16,282 -2,922 -15.22 169 -19.23 0.0002
2023-05-12 2023-03-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 19,204 -24,397 -55.96 208 -57.46 0.0003
2023-02-14 2022-12-31 13F Theravance Biopharma Equity G8807B106 43,601 27,644 173.24 489 203.73 0.0008
2022-11-16 2022-09-30 13F/A-1 Theravance Biopharma Equity G8807B106 15,957 -92,693 -85.31 162 -83.64 0.0003
2022-11-15 2022-09-30 13F Theravance Biopharma Equity G8807B106 15,957 -92,693 162 0.0000
2022-08-12 2022-06-30 13F Theravance Biopharma Equity G8807B106 108,650 -15,584 -12.54 984 -17.10 0.0015
2022-05-18 2022-03-31 13F/A-1 Theravance Biopharma Equity G8807B106 124,234 47,509 61.92 1,188 40.14 0.0016
2022-02-09 2021-12-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 76,725 65,935 611.08 848 972.15 0.0012
2021-11-16 2021-09-30 13F/A-1 THERAVANCE BIOPHARMA EQUITY G8807B106 10,790 8,717 420.50 80 163.33 0.0001
2021-11-12 2021-09-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 11,004 8,931 163 0.0000
2021-08-10 2021-06-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 2,073 -4,955 -70.50 30 -79.02 0.0000
2021-05-07 2021-03-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 7,028 -2,721 -27.91 143 -17.34 0.0002
2021-02-10 2020-12-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 9,749 -1,255 -11.40 173 6.79 0.0003
2020-10-30 2020-09-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 11,004 7,953 260.67 163 153.13 0.0002
2020-08-06 2020-06-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 3,051 -12,880 -80.85 64 -82.61 0.0001
2020-05-13 2020-03-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 15,931 9,802 159.93 368 132.91 0.0008
2020-02-12 2019-12-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 6,129 -1,750 -22.21 159 3.27 0.0003
2019-11-07 2019-09-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 7,879 2,088 36.06 153 62.77 0.0003
2019-07-30 2019-06-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 5,791 -4,174 -41.89 95 -58.22 0.0002
2019-04-25 2019-03-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 9,965 8,951 882.74 226 800.00 0.0005
2019-02-12 2018-12-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 1,014 -1,363 -57.34 26 -67.53 0.0001
2018-11-07 2018-09-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 2,377 180 8.19 78 57.14 0.0001
2018-07-25 2018-06-30 13F THERAVANCE BIOPHARMA EQUITY G8807B106 2,197 -6,863 -75.75 50 -77.63 0.0001
2018-05-11 2018-03-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 9,060 395 4.56 220 -9.13 0.0004
2018-03-05 2017-12-31 13F/A-1 THERAVANCE BIOPHARMA EQUITY G8807B106 8,665 3,797 78.00 242 45.18 0.0004
2018-02-01 2017-12-31 13F THERAVANCE BIOPHARMA EQUITY G8807B106 8,665 3,797 242
2017-11-03 2017-09-30 13F THERAVANCE BIOPHARMA STOCK G8807B106 4,868 -283 -5.49 167 -19.02 0.0004
2017-08-03 2017-06-30 13F THERAVANCE BIOPHARMA STOCK G8807B106 5,151 4,383 570.70 205 632.14 0.0006
2017-05-03 2017-03-31 13F THERAVANCE BIOPHARMA STOCK G8807B106 768 -1,925 -71.48 28 -67.06 0.0001
2017-02-14 2016-12-31 13F THERAVANCE BIOPHARMA STOCK G8807B106 2,693 -315 -10.47 86 -22.02 0.0004
2016-10-05 2016-09-30 13F * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 3,008 1,577 110.20 109 240.63 0.0004
2016-07-06 2016-06-30 13F * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 1,431 1,431 0.00 32 0.0001
2016-04-22 2016-03-31 13F * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 0 -3,101 -100.00 0 -100.00
2016-04-19 2015-12-31 13F/A-1 * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 3,101 -2,118 -40.58 51 -12.28 0.0002
2016-02-10 2015-12-31 13F * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 3,101 51
2015-11-13 2015-09-30 13F * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 5,219 2,938 128.80 57 96.55 0.0001
2015-08-14 2015-06-30 13F THERAVANCE BIOPHARMA INC COM STOCK G8807B106 2,281 1,721 307.32 30 222.22 0.0001
2015-05-15 2015-03-31 13F * THERAVANCE BIOPHARMA INC COM STOCK G8807B106 560 560 0.00 10 0.0000
2015-02-11 2014-12-31 13F * THERAVANCE BIOPHARMA INC COM ADDED STOCK G8807B106 0 -1,406 -100.00 0 -100.00
2014-11-12 2014-09-30 13F * THERAVANCE BIOPHARMA INC COM ADDED STOCK G8807B106 1,406 1,406 32 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.